Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Plos One|June 13, 2015
Genetic Variants in Caveolin-1 and RhoA/ROCK1 Are Associated with Clear Cell Renal Cell Carcinoma Risk in a Chinese PopulationRuizhe Zhao, Kang Liu, Zhengkai Huang, et al.
Molecular and Cellular Biochemistry|January 4, 2011
miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRASBin Xu, Xiaobing Niu, Xiangxiang Zhang, et al.
Biochemical and Biophysical Research Communications|February 13, 2013
Fenofibrate down-regulates the expressions of androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate cancer cell line LNCaPHu Zhao, Chen Zhu, Chao Qin, et al.
Molecular Biology Reports|May 11, 2011
A miR-125b binding site polymorphism in bone morphogenetic protein membrane receptor type IB gene and prostate cancer risk in ChinaNinghan Feng, Bin Xu, Jun Tao, et al.
The Prostate|March 6, 2013
miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell linesChen Zhu, Jie Li, Qi Ding, et al.
Molecular and Cellular Biochemistry|April 18, 2013
miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cellsChen Zhu, Jie Li, Gong Cheng, et al.
Plos One|March 4, 2014
Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese populationJian Qian, Hai Zhou, Jiawei Chen, et al.
Oncotarget|October 4, 2017
Positive expression of NR6A1/CT150 as a predictor of biochemical recurrence-free survival in prostate cancer patientsGong Cheng, Shangqian Wang, Xiao Li, et al.
The Prostate|March 25, 2010
A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expressionBin Xu, Jinfeng Wang, Na Tong, et al.
Signal Transduction and Targeted Therapy|April 12, 2026
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trialJunlong Wu, Xinghai Li, Chengyuan Gu, et al.
Pageof 7